DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 20912-S021
NDA 20913-S018

SUPPLEMENT APPROVAL

Medicure International Inc.
Attention: Lois Inniss
Treasurer
St James House
Second Street, Holetown
St James, BB 24016, Barbados

Dear Ms. Inniss:

Please refer to your Supplemental New Drug Application (sNDA) dated 24 October 2014, received 24 October 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for AGGRASTAT (tirofiban hydrochloride) Injection.

This Prior Approval supplemental new drug application proposes changes to dosage and administration detailing that the infusion time can be within five minutes.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text. Those changes are as follows:

- The section in the Highlights, **RECENT MAJOR CHANGES** only captures changes that are less than 1-year old, therefore, Indications and Usage was removed.
- In **DOSAGE AND ADMINISTRATION**, the following revisions were made:
  - The infusion time was changed from "over 3 minutes" to "within 5 minutes".
  - This change was also reflected in Table 1, Dosing by Weight and CrCl.
- In **CLINICAL PHARMACOLOGY**, subsection 12.1 (**Mechanism of Action**), the mention of an infusion time of three minutes was removed.
- The above changes were also reflected in the Highlights.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of

labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable. Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Alison Blaus, Sr. Regulatory Project Manager, at (301) 796-1138.

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, PharmD
Deputy Director for Safety
Division of Cardiovascular & Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc: Medicure Pharma Inc.
Attention: Dawson Reimer, President & COO
US Agent for Medicure International Inc.
500 Atrium Drive
Somerset, NJ 08873

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ALISON L BLAUS
04/21/2015

MARY R SOUTHWORTH
04/21/2015